
Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2B Deal
nicolas_ Deals and Financings Legend Biotech (LEGN), a New Jersey-Nanjing CAR-T biotech, partnered its DLL3 (delta-like ligand 3) CAR-T candidates to Novartis (NVS) in a $1.2 billion agreement ($100 million upfront) (see story). Legend will […]